An MRI Ancillary Study of Malaria Fever Control RCT
An MRI Ancillary Study of Malaria Fever Control RCT
批准号:
10556361
负责人:
GRETCHEN L. BIRBECK
金额:
$24.55万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-03-15 至 2025-01-31
关键词:
AcetaminophenAcuteAdverse effectsAdverse eventAffectAfricanAgeAncillary StudyAnti-Inflammatory AgentsAntiinflammatory EffectAutopsyBehavior assessmentBlindedBloodBlood PlateletsBrainBrain InjuriesCaringChildChild CareChildhoodClinical TreatmentClinical TrialsClinical Trials Data Monitoring CommitteesDataEarly identificationEnrollmentEvaluationEvolutionFeverFutureGoalsGuidelinesHemorrhageHemosiderinIbuprofenImageInfrastructureInjuryInterventionIntervention TrialIntraventricularLesionLinkLocationLongterm Follow-upMagnetic Resonance ImagingMalariaMalawiMediatingMethodsNegative FindingNeurologicNeurological outcomeOutcomePathway interactionsPhasePopulationPrevalencePropertyProxyRandomized, Controlled TrialsRecoveryResearchResearch DesignResidual stateRiskRisk FactorsSeveritiesStainsStructural defectTemperatureZambiaacute infectionantipyreticblood productbrain abnormalitiescognitive testingdesignfollow-upinsightmalaria infectionneuroimagingneuroprotectionprimary outcomeprogramsradiologistroutine carescale uptooltreatment as usualtreatment responsetreatment stratificationtreatment-related injury
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Contact PD/PI: BIRBECK, GRETCHEN L.
ABSTRACT
Despite eradication efforts, ~400,000 African children sustained brain injuries as a result of CNS malaria in
2016. A higher maximum temperature (Tmax) during the acute malaria infection is an established risk factor for
neurologic sequelae and a randomized controlled trial (RCT) of aggressive antipyretic therapy with
acetaminophen and ibuprofen began enrollment in Malawi in 2019 (R01NS102176) with expansion into
Zambia pending. In this clinical trial, the primary outcome is Tmax during the acute infection. However, the
antipyretic therapies used in this RCT may offer neuroprotective benefits without affecting Tmax--for example,
neuroprotection through anti-inflammatory mechanisms. In this ancillary study, we propose to use
neuroimaging in the context of the RCT to further evaluate the potential neuroprotective effects of aggressive
antipyretic therapy for CNS malaria and explore possible mechanisms for these effects. Comparing children
allocated to aggressive antipyretic therapy vs. usual care on the prevalence of structural brain abnormalities
after recovery from CNS malaria will facilitate the evaluation of non-fever pathways for neuroprotection. Both
Zambia and Malawi have an unusually well developed infrastructure for advanced imaging in the academic
Brain MRIs will be obtained in
children enrolled in the RCT at 1- and 12-months post recovery. Analyses will be completed comparing the
odds of having any structural injury based upon RCT treatment allocation and based upon (Tmax) stratified by
treatment allocation to assess changes specifically related to response to therapy in terms of fever reduction.
Potential mechanisms of aggressive antipyretic-related injury will be evaluated including assessments for
treatment-related CNS bleeds. Neuroimaging is a well-established, valid proxy for neurological outcomes after
brain injury including in pediatric CNS malaria. Adding this MRI ancillary study to our fever RCT may elucidate
mechanisms of treatment-associated injury and allow for early identification of neuroprotection from aggressive
antipyretic use that would otherwise require long-term follow-up for cognitive and behavioral assessments. This
MRI ancillary study when added to the Fever RCT will provide critical insights that could inform future
neuroprotective studies of malaria that might incorporate imaging to optimize study design.
centers where the RCT using aggressive antipyretic therapy will be conducted.
Page 7
Project Summary/Abstract
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Global Research Endeavors to Advance Treatment of Neurological Disorders in Africa (GREAT Neurology)
-
批准号:10611348
-
项目类别:
-
资助金额:$52.72万
-
财政年份:2021
-
负责人:GRETCHEN L. BIRBECK
-
依托单位:
Global Research Endeavors to Advance Treatment of Neurological Disorders in Africa (GREAT Neurology)
-
批准号:10397647
-
项目类别:
-
资助金额:$52.19万
-
财政年份:2021
-
负责人:GRETCHEN L. BIRBECK
-
依托单位:
Global Research Endeavors to Advance Treatment of Neurological Disorders in Africa (GREAT Neurology)
-
批准号:10238395
-
项目类别:
-
资助金额:$44.78万
-
财政年份:2021
-
负责人:GRETCHEN L. BIRBECK
-
依托单位:
An MRI Ancillary Study of Malaria Fever Control RCT
-
批准号:10343754
-
项目类别:
-
资助金额:$24.66万
-
财政年份:2020
-
负责人:GRETCHEN L. BIRBECK
-
依托单位:
Collaborative HIV Investigations of Antiretroviral Neuropsychiatric Toxicities in Zambia (CHANTZ): Protease Inhibitor Impact on Pediatric Cerebrovasculature and Mood
-
批准号:10252756
-
项目类别:
-
资助金额:$16.58万
-
财政年份:2020
-
负责人:GRETCHEN L. BIRBECK
-
依托单位:
An MRI Ancillary Study of Malaria Fever Control RCT
-
批准号:10117293
-
项目类别:
-
资助金额:$28.27万
-
财政年份:2020
-
负责人:GRETCHEN L. BIRBECK
-
依托单位:
Collaborative HIV Investigations of Antiretroviral Neuropsychiatric Toxicities in Zambia (CHANTZ): Protease Inhibitor Impact on Pediatric Cerebrovasculature and Mood
-
批准号:9925503
-
项目类别:
-
资助金额:$23.28万
-
财政年份:2020
-
负责人:GRETCHEN L. BIRBECK
-
依托单位:
An MRI Ancillary Study of Malaria Fever Control RCT
-
批准号:9884625
-
项目类别:
-
资助金额:$31.75万
-
财政年份:2020
-
负责人:GRETCHEN L. BIRBECK
-
依托单位:
Aggressive Antipyretics in CNS Malaria: A Randomized-Controlled Trial Assessing Antipyretic Efficacy and Parasite Clearance
-
批准号:9923006
-
项目类别:
-
资助金额:$63.88万
-
财政年份:2017
-
负责人:GRETCHEN L. BIRBECK
-
依托单位:
Aggressive Antipyretics in CNS Malaria: A Randomized-Controlled Trial Assessing Antipyretic Efficacy and Parasite Clearance
-
批准号:10179500
-
项目类别:
-
资助金额:$60.25万
-
财政年份:2017
-
负责人:GRETCHEN L. BIRBECK
-
依托单位:
Cohort of HIV-Associated Seizures and Epilepsy in Zambia (CHASE): Scale up and expansion informed by R21 Findings
-
批准号:9336983
-
项目类别:
-
资助金额:$56.09万
-
财政年份:2015
-
负责人:GRETCHEN L. BIRBECK
-
依托单位:
Cohort of HIV-Associated Seizures and Epilepsy in Zambia (CHASE): Scale up and expansion informed by R21 Findings
-
批准号:8990936
-
项目类别:
-
资助金额:$61.91万
-
财政年份:2015
-
负责人:GRETCHEN L. BIRBECK
-
依托单位:
Cohort of HIV-Associated Seizures and Epilepsy in Zambia (CHASE): Scale up and expansion informed by R21 Findings
-
批准号:9927078
-
项目类别:
-
资助金额:$13.76万
-
财政年份:2015
-
负责人:GRETCHEN L. BIRBECK
-
依托单位:
Cohort of HIV-Associated Seizures and Epilepsy in Zambia (CHASE): Scale up and expansion informed by R21 Findings
-
批准号:9751402
-
项目类别:
-
资助金额:$57.51万
-
财政年份:2015
-
负责人:GRETCHEN L. BIRBECK
-
依托单位:
A DOSE-ESCALATION, SAFETY AND FEASIBILITY STUDY OF ENTERAL LEVETIRACETAM FOR SEIZ
-
批准号:8302847
-
项目类别:
-
资助金额:$71.22万
-
财政年份:2012
-
负责人:GRETCHEN L. BIRBECK
-
依托单位:
A Dose-Escalation, Safety and Feasibility Study of Enteral Levetiracetam for Seizure Control in Pediatric Cerebral Malaria
-
批准号:8739553
-
项目类别:
-
资助金额:$54.7万
-
财政年份:2012
-
负责人:GRETCHEN L. BIRBECK
-
依托单位:
A Dose-Escalation, Safety and Feasibility Study of Enteral Levetiracetam for Seizure Control in Pediatric Cerebral Malaria
-
批准号:8714332
-
项目类别:
-
资助金额:$57.23万
-
财政年份:2012
-
负责人:GRETCHEN L. BIRBECK
-
依托单位:
A Cohort Study of Seizures and Epilepsy in HIV+ Zambian Adults
-
批准号:8217127
-
项目类别:
-
资助金额:$11.9万
-
财政年份:2011
-
负责人:GRETCHEN L. BIRBECK
-
依托单位:
A Cohort Study of Seizures and Epilepsy in HIV+ Zambian Adults
-
批准号:8073288
-
项目类别:
-
资助金额:$12.58万
-
财政年份:2011
-
负责人:GRETCHEN L. BIRBECK
-
依托单位:
THE MALAWI-MSU MRI PROJECT: AN EPIDEMIOLOGIC STUDY OF CNS ABNORMALITIES
-
批准号:8133641
-
项目类别:
-
资助金额:$5.42万
-
财政年份:2010
-
负责人:GRETCHEN L. BIRBECK
-
依托单位:
海外基金